GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Classement en actions
#3668
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Prix de l'action
$27.17
Capitalisation boursière
$4.60B
Changement (1 jour)
-1.33%
Changement (1 an)
-13.30%
Pays
IN
Échange GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Catégorie
Healthcare
Bénéfices pour GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Bénéfices en Jun 2026 TTM : $159.96M
Selon les derniers rapports financiers de GlaxoSmithKline Pharmaceuticals Limited, les bénéfices actuels de l'entreprise sont de $159.96M. En 2024, l'entreprise a réalisé un bénéfice de $97.88M, une diminution par rapport à celui de 2023 qui était de $101.78M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour GlaxoSmithKline Pharmaceuticals Limited de 2004 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $159.96M | 8.59% |
| 2025 | $147.31M | 50.49% |
| 2024 | $97.88M | -3.82% |
| 2023 | $101.78M | -0.83% |
| 2022 | $102.63M | 65.48% |
| 2021 | $62.02M | 52.81% |
| 2020 | $40.59M | -58.72% |
| 2019 | $98.31M | 18.54% |
| 2018 | $82.93M | 5.21% |
| 2017 | $78.83M | -9.71% |
| 2016 | $87.30M | -9.89% |
| 2015 | $96.88M | -0.90% |
| 2013 | $97.77M | -35.64% |
| 2012 | $151.90M | -13.05% |
| 2011 | $174.69M | -10.43% |
| 2010 | $195.02M | 19.11% |
| 2009 | $163.74M | 13.31% |
| 2008 | $144.51M | -9.37% |
| 2007 | $159.46M | 24.82% |
| 2006 | $127.75M | 17.87% |
| 2005 | $108.38M | 10.05% |
| 2004 | $98.49M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $33.60B | 20,902.13% |
US
|
|
| $17.74B | 10,988.20% |
US
|
|
| $8.70B | 5,338.14% |
US
|
|
| $5.95B | 3,618.36% |
US
|
|
| $21.39B | 13,270.79% |
CH
|
